The Oncology Institute, Inc. $TOI is BRC Group Holdings Inc.’s 7th Largest Position

BRC Group Holdings Inc. cut its position in shares of The Oncology Institute, Inc. (NASDAQ:TOI) by 18.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 663,376 shares of the company’s stock after selling 148,170 shares during the quarter. Oncology Institute accounts for 1.0% of BRC Group Holdings Inc.’s portfolio, making the stock its 7th largest position. BRC Group Holdings Inc. owned about 0.67% of Oncology Institute worth $2,362,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently bought and sold shares of the company. Pekin Hardy Strauss Inc. acquired a new stake in Oncology Institute during the 4th quarter worth about $36,000. Cetera Investment Advisers boosted its position in Oncology Institute by 35.0% during the 2nd quarter. Cetera Investment Advisers now owns 17,545 shares of the company’s stock worth $36,000 after acquiring an additional 4,545 shares during the period. State of Wyoming acquired a new stake in Oncology Institute during the 2nd quarter worth about $37,000. R Squared Ltd acquired a new stake in Oncology Institute during the 4th quarter worth about $41,000. Finally, Prelude Capital Management LLC acquired a new stake in Oncology Institute during the 3rd quarter worth about $41,000. 36.86% of the stock is owned by hedge funds and other institutional investors.

Oncology Institute Price Performance

TOI opened at $4.69 on Friday. The Oncology Institute, Inc. has a fifty-two week low of $2.02 and a fifty-two week high of $4.88. The business has a 50-day moving average of $3.65 and a 200-day moving average of $3.35. The company has a market capitalization of $463.56 million, a PE ratio of -12.68 and a beta of 0.33.

Oncology Institute (NASDAQ:TOI) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.05. The firm had revenue of $147.44 million for the quarter, compared to analysts’ expectations of $142.10 million. On average, equities research analysts expect that The Oncology Institute, Inc. will post -0.17 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Jorey Chernett acquired 263,000 shares of the business’s stock in a transaction that occurred on Friday, March 13th. The shares were acquired at an average cost of $2.92 per share, with a total value of $767,960.00. Following the purchase, the insider owned 10,115,944 shares of the company’s stock, valued at approximately $29,538,556.48. The trade was a 2.67% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mohit Kaushal sold 57,286 shares of the firm’s stock in a transaction that occurred on Tuesday, April 14th. The shares were sold at an average price of $3.50, for a total value of $200,501.00. Following the completion of the transaction, the director directly owned 211,016 shares in the company, valued at $738,556. The trade was a 21.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders purchased a total of 637,485 shares of company stock worth $2,038,896 over the last three months. 8.50% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

TOI has been the subject of a number of research reports. B. Riley Financial raised their price objective on Oncology Institute from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. BTIG Research restated a “buy” rating and set a $7.00 price objective on shares of Oncology Institute in a research report on Monday, March 9th. Needham & Company LLC restated a “buy” rating and set a $5.00 price objective on shares of Oncology Institute in a research report on Monday, March 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Oncology Institute in a research report on Monday, April 20th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Oncology Institute has an average rating of “Moderate Buy” and a consensus target price of $7.00.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.